BUZZ-GT 生物制药公司因 FDA 批准癌症新药人体试验而大涨

路透中文

Feb 03

2月3日 - ** 药物开发商GT生物制药公司GTBP.O股价盘前上涨17.9%至0.60美元

** 该公司称美国FDA批准了其实验性药物GTB-5550用于晚期癌症的人体试验

** 该药物旨在帮助免疫细胞攻击携带 B7-H3 的肿瘤，B7-H3 是一种常见于前列腺癌、卵巢癌、胰腺癌和其他实体瘤的蛋白质。

** 早期研究将采用短治疗周期和多剂量水平测试安全性；公司计划在安全性检查后将研究扩展到最多七种癌症 - GTBP

** 2025 年股价下跌约 74%

(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2608874670"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2608874670\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2608874670?lang=en_US&edition=fundamental","thumbnail":"","is_english":false,"pubTime":"2026-02-03 21:45","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2608874670","market":"hk","top_or_hot":-1,"title":"BUZZ-GT 生物制药公司因 FDA 批准癌症新药人体试验而大涨","media":"路透中文","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BUZZ-GT 生物制药公司因 FDA 批准癌症新药人体试验而大涨</title></head><body><p><span>2月3日</span><span> - </span>** 药物开发商GT生物制药公司<span>GTBP.O</span>股价盘前上涨17.9%至0.60美元</p><p>** 该公司称美国FDA批准了其实验性药物GTB-5550用于晚期癌症的人体试验</p><p>** 该药物旨在帮助免疫细胞攻击携带 B7-H3 的肿瘤，B7-H3 是一种常见于前列腺癌、卵巢癌、胰腺癌和其他实体瘤的蛋白质。</p><p>** 早期研究将采用短治疗周期和多剂量水平测试安全性；公司计划在安全性检查后将研究扩展到最多七种癌症 - GTBP</p><p>** 2025 年股价下跌约 74%</p><p>(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BUZZ-GT 生物制药公司因 FDA 批准癌症新药人体试验而大涨</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBUZZ-GT 生物制药公司因 FDA 批准癌症新药人体试验而大涨\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1098195322\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">路透中文 </p>\n<p class=\"h-time\">2026-02-03 21:45</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BUZZ-GT 生物制药公司因 FDA 批准癌症新药人体试验而大涨</title></head><body><p><span>2月3日</span><span> - </span>** 药物开发商GT生物制药公司<span>GTBP.O</span>股价盘前上涨17.9%至0.60美元</p><p>** 该公司称美国FDA批准了其实验性药物GTB-5550用于晚期癌症的人体试验</p><p>** 该药物旨在帮助免疫细胞攻击携带 B7-H3 的肿瘤，B7-H3 是一种常见于前列腺癌、卵巢癌、胰腺癌和其他实体瘤的蛋白质。</p><p>** 早期研究将采用短治疗周期和多剂量水平测试安全性；公司计划在安全性检查后将研究扩展到最多七种癌症 - GTBP</p><p>** 2025 年股价下跌约 74%</p><p>(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260203:nL4S3YZ1DK:1","article_id":"2608874670","we_media_id":"1098195322","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2608874670","pubTimestamp":1770126305,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"路透中文","introduction":"路透中文","home_visible":1,"id":"1098195322","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BUZZ-GT 生物制药公司因 FDA 批准癌症新药人体试验而大涨2月3日 - ** 药物开发商GT生物制药公司GTBP.O股价盘前上涨17.9%至0.60美元** 该公司称美国FDA批准了其实验性药物GTB-5550用于晚期癌症的人体试验** 该药物旨在帮助免疫细胞攻击携带 B7-H3 的肿瘤，B7-H3 是一种常见于前列腺癌、卵巢癌、胰腺癌和其他实体瘤的蛋白质。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"zh","relate_stocks":{"BK4139":"生物科技","GTBP":"GT Biopharma Inc."},"translate_title":"BUZZ-GT Biopharmaceutical surges on FDA approves human trial of new cancer drug","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"GTBP":0.9},"content_text":"BUZZ-GT 生物制药公司因 FDA 批准癌症新药人体试验而大涨2月3日 - ** 药物开发商GT生物制药公司GTBP.O股价盘前上涨17.9%至0.60美元** 该公司称美国FDA批准了其实验性药物GTB-5550用于晚期癌症的人体试验** 该药物旨在帮助免疫细胞攻击携带 B7-H3 的肿瘤，B7-H3 是一种常见于前列腺癌、卵巢癌、胰腺癌和其他实体瘤的蛋白质。** 早期研究将采用短治疗周期和多剂量水平测试安全性；公司计划在安全性检查后将研究扩展到最多七种癌症 - GTBP** 2025 年股价下跌约 74%(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"shareholding,corporation","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}